JPMorgan has lowered its outlook for Abbott India due to concerns about the company's growth, now categorizing it as 'Neutral'. The revised target suggests a more cautious view on the company's potential returns.

JPMorgan has reduced its stance on Abbott India to neutral and lowered the price target by nearly 20%, due to growth concerns. However, Abbott's collaboration with Novo Nordisk for semaglutide marketing has helped the stock rise 1.2% today, despite a 10% decrease year-to-date in 2026.